Refractory Non-Hodgkin's lymphoma Not Yet Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Refractory Non Hodgkin Lymphoma / Refractory Non-Hodgkin Lymphoma / Refractory Non-Hodgkin Lympoma / Refractory Non-Hodgkin-Lymphoma / Non-Hodgkin's lymphoma refractory / Non-Hodgkin's lymphoma NOS refractory

IndicationStatusPhase
DBCOND0024997 (Refractory Non-Hodgkin's lymphoma)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04205409Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesTreatment